博安生物(06955.HK)：中期归母净利润2051.4万元 同比减少66.7%

Core Insights - The company reported a revenue of RMB 393 million for the six months ending June 30, 2025, representing an 8.4% year-on-year increase [1] - Gross profit remained relatively stable at RMB 283 million, showing no significant change compared to the previous period [1] - Net profit attributable to the parent company decreased by 66.7% to RMB 20.514 million, with basic earnings per share at RMB 0.04 [1] - The increase in revenue was primarily driven by a 15.9% growth in sales of key products (博优诺®, 博优倍®, and 博洛加®), totaling RMB 385.3 million [1]